



**UNICHEM
LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198

Tel. No. : 91 (22) 66888333

Website : <http://www.unichemlabs.com>

CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

Ref: ULL/SEC/2016-17

Date : June 10, 2016

Corporate Relation Department
Bombay Stock Exchange Ltd.
1st Floor, Rotunda Bulding
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor
Plot No.C/1, G Block
Bandra– Kurla Complex
Bandra (East), Mumbai – 400 051

Ref: BSE Scrip Code: 506690 : NSE Symbol – UNICHEMLAB

Dear Sir,

This is with reference to our letter dated May 20, 2016, whereby we had sent to the exchange, the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2016 along with the auditor's report and Form A duly approved by the Board of Directors at its Meeting held on May 20, 2016.

We had by inadvertence sent the Independent auditors report ((standalone and consolidated) as prepared under the provisions of the Companies Act, 2013 and the Rules made there under instead of the auditor's report as required under the format prescribed under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby enclose the Auditors Report for standalone and consolidated audited financial results as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Request you to kindly the same on record.

Thanking you,

Yours Faithfully,

For UNICHEM LABORATORIES LIMITED

NEEMA THAKORE

Head - Legal & Company Secretary

Encl: As Above

Auditor's Report On Consolidated Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Unichem Laboratories Limited

We have audited the consolidated year to date results of Unichem Laboratories Limited ("the Company") for the period 1st April, 2015 to 31st March, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These consolidated year to date financial results have been prepared on the basis of the audited consolidated financial statements for the year ended on 31st March, 2016, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of the consolidated financial statements for the year ended 31st March, 2016 which have been prepared in accordance with the applicable accounting standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements of five subsidiaries included in the consolidated year to date results, whose consolidated financial statements reflect total assets (net) of Rs. 1,944.39 lacs as at March 31, 2016 and the total revenues (including other income) of Rs. 29,946.59 lacs for the period then ended. These financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the year to date results, in so far as it relates to the amounts included in respect of subsidiaries is based solely on the report of such other auditors. Our opinion is not qualified in respect of this matter.

In our opinion and to the best of our information and according to the explanations given to us, these consolidated year to date results:

- (i) include the year to date results of the following entities
 - (a) Niche Generics Limited, United Kingdom
 - (b) Unichem Pharmaceuticals (USA), Inc., USA
 - (c) Unichem Laboratories Limited, Ireland
 - (d) Unichem SA (Pty) Limited, South Africa
 - (e) Unichem Farmaceutica Do Brasil Ltda, Brazil;
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the consolidated year to date results for the period from 1st April, 2015 to 31st March, 2016.

Place: Mumbai
Date: May 20, 2016



For B. D. Jokhakar & Co.
Chartered Accountants
Firm Registration No.: 104345W

Raman H. Jokhakar
Partner

Membership No. 103241

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Unichem Laboratories Limited

We have audited the quarterly financial results of Unichem Laboratories Limited("the Company") for the quarter ended 31st March, 2016 and the year to date results for the period 1st April, 2015 to 31st March, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly and year to date financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2016 as well as the year to date results for the period from 1st April, 2015 to 31st March, 2016.

Place: Mumbai
Date: May 20, 2016



For B. D. Jokhakar & Co.
Chartered Accountants
Firm Registration No. : 104345W

Raman H. Jokhakar
Partner
Membership No. : 103241



UNICHEM LABORATORIES LTD.

Fax No : 91 (22) 2678 4391 / 5198

Tel. No. : 91 (22) 66888333

Website : <http://www.unichemlabs.com>

CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

PART I							
Statement of Audited Financial Results for the Quarter and Year ended 31st March, 2016.							
₹ Lacs							
Particulars	Standalone			Standalone Audited		Consolidated Audited	
	Three months ended 31st Mar'16 (Audited)	Three months ended 31st Dec'15 (Unaudited)	Three months ended 31st Mar'15 (Audited)	Accounting Year ended 31st Mar'16 (Audited)	Accounting year ended 31st Mar'15 (Audited)	Accounting Year ended 31st Mar'16 (Audited)	Accounting Year ended 31st Mar'15 (Audited)
INCOME FROM OPERATIONS							
1 a) Net Sales/Income from operations (Net of excise duty)	29,213.29	30,393.17	25,055.61	120,434.73	107,689.95	131,649.97	118,770.83
b) Other Operating Income	938.47	232.95	543.40	1,806.41	1,408.51	1,806.41	1,408.51
TOTAL INCOME FROM OPERATIONS (NET)	30,151.76	30,626.12	25,599.01	122,241.14	109,098.46	133,456.38	120,179.34
EXPENSES							
2 a) Cost of Materials Consumed	8,331.55	7,633.18	6,713.86	32,319.94	30,618.22	36,008.16	34,278.92
b) Purchases of stock-in-trade	3,401.15	3,185.17	1,997.86	13,752.69	12,934.66	11,655.18	11,317.65
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(951.80)	18.42	946.04	(871.23)	(769.16)	(1,865.56)	(1,364.17)
d) Employee benefits expense	5,628.90	5,894.01	4,630.17	22,580.28	19,138.87	27,211.82	23,654.72
e) Depreciation and amortisation expense	880.95	872.20	798.00	3,499.12	3,768.30	3,900.11	4,127.24
f) Other expenses	10,621.09	10,485.61	9,829.23	40,218.91	37,017.60	44,055.96	42,157.64
TOTAL EXPENSES	27,911.84	28,088.59	24,915.16	111,499.71	102,708.49	120,966.67	114,172.00
3 Profit/(Loss) from operations before other income, finance costs and Other income	2,239.92	2,537.53	683.85	10,741.43	6,389.97	12,490.71	6,007.34
4 Profit/(Loss) from ordinary activities before finance costs and exceptional Finance costs	582.95	459.15	551.43	2,265.50	1,996.77	1,918.59	2,038.28
5 Profit/(Loss) from ordinary activities before tax & exceptional items (5-6)	2,822.87	2,996.68	1,235.28	13,006.93	8,386.74	14,409.30	8,045.62
6 Finance costs	78.27	44.23	42.22	228.09	236.97	288.56	304.29
7 Profit/(Loss) from ordinary activities after tax but before exceptional (7-8)	2,744.60	2,952.45	1,193.06	12,778.84	8,149.77	14,120.74	7,741.33
8 Tax Expenses	(70.03)	620.00	211.05	2,443.97	1,710.05	3,002.38	213.22
9 Profit/(Loss) from ordinary activities after tax but before exceptional (7-8)	2,814.63	2,332.45	982.01	10,334.87	6,439.72	11,118.36	7,528.11
10 Exceptional Item (Refer Note 5 below)	-	353.00	-	353.00	-	353.00	-
11 Tax on exceptional items	-	(75.00)	-	(75.00)	-	(75.00)	-
12 Share in Profit / (Loss) of Associates	-	-	-	-	-	(36.95)	10.90
13 Net profit from ordinary activities after tax, exceptional items & share of	2,814.63	2,054.45	982.01	10,056.87	6,439.72	10,803.41	7,539.01
14 Paid up Equity Share Capital (Face Value Rs. 2 per share)	1,816.87	1,816.48	1,815.38	1,816.87	1,815.38	1,816.87	1,815.38
15 Reserves excluding Revaluation Reserve as per balance sheet of previous	-	-	-	100,896.36	92,926.18	93,666.69	84,936.64
16 Earning Per Share (Face Value of Rs. 2/ each) Before Exceptional items							
a) Basic - Rs.	3.10	2.57	1.08	11.38	7.10	12.20	8.31
b) Diluted - Rs.	3.09	2.56	1.08	11.36	7.08	12.18	8.29
17 Earning Per Share (Face Value of Rs. 2/ each) After Exceptional items							
a) Basic - Rs.	3.10	2.26	1.08	11.07	7.10	11.90	8.31
b) Diluted - Rs.	3.09	2.26	1.08	11.05	7.08	11.87	8.29

Notes :

- The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 20th May, 2016.
- The Board of Directors has recommended that the Interim Dividend of Rs. 2/- per equity share paid on 28th March, 2016 be considered as final dividend for the year ended 31st March, 2016.
- Segment Reporting:
Primary Segment
The Company has only one segment i.e. 'Pharmaceuticals'.

UNICHEM-A TRUSTED NAME IN PHARMACEUTICALS



UNICHEM LABORATORIES LTD.

Fax No : 91 (22) 2678 4391 / 5198

Tel. No. : 91 (22) 66888333

Website : <http://www.unichemlabs.com>

CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

Secondary Segment (By Geographical Segment)

Net Sales and Operating Income	Three months ended 31st Mar'16 (Audited)	Three months ended 31st Dec'15 (Unaudited)	Three months ended 31st Mar'15 (Audited)	Accounting Year ended 31st Mar'16 (Audited)	Accounting year ended 31st Mar'15 (Audited)	Accounting Year ended 31st Mar'16 (Audited)	Accounting Year ended 31st Mar'15 (Audited)
Within India	17,508.71	19,316.76	15,111.21	76,563.35	67,528.64	76,563.35	67,528.64
Outside India	12,643.05	11,309.36	10,487.80	45,677.79	41,569.82	56,893.03	52,650.70
Total	30,151.76	30,626.12	25,599.01	122,241.14	109,098.46	133,456.38	120,179.34

In view of the interwoven / intermix nature of the business and manufacturing facility, other segmental information is not ascertainable.

4 Other Income includes exchange gain / (loss) as under:

Exchange Difference	Three months ended 31st Mar'16 (Audited)	Three months ended 31st Dec'15 (Unaudited)	Three months ended 31st Mar'15 (Audited)	Accounting Year ended 31st Mar'16 (Audited)	Accounting year ended 31st Mar'15 (Audited)
Exchange gain included in other income	183.74	127.89		811.99	278.59
Exchange loss included in other expenses			126.20		

- 5 Enactment of The Payment of Bonus (Amendment) Act , 2015 having come into force effective 1st day of April 2014 the Company has made additional
- Pertaining to the period from 1st April 2015 to 31st March 2016 is included in Employee benefits expenses.
 - Pertaining for the period from 1st April 2014 to 31st March 2015 is disclosed as an Exceptional item.

Audited Statement of Assets and

Liabilities as on 31st, March 2016

Particulars	Standalone Audited		Consolidated Audited	
	As at 31.03.2016	As at 31.03.2015	As at 31.03.2016	As at 31.03.2015
I. EQUITY AND LIABILITIES				
(1) Shareholders' Funds				
(a) Share Capital	1,816.87	1,815.38	1,816.87	1,815.38
(b) Reserve & Surplus	100,896.36	92,926.18	93,666.69	84,936.64
	102,713.23	94,741.56	95,483.56	86,752.02
(2) Non Current Liabilities				
(a) Long term borrowings	51.44	22.08	2,303.67	2,034.61
(b) Deferred tax liabilities (Net)	3,131.54	3,932.54	3,131.54	3,932.54
(c) Other Long term liabilities	1,930.77	2,084.55	1,930.77	2,084.55
(d) Long term provisions	1,257.55	887.56	1,257.55	887.56
	6,371.30	6,926.73	8,623.53	8,939.26
(3) Current Liabilities				
(a) Short term borrowings	790.15	-	1,292.50	162.57
(b) Trade payables	18,963.35	14,262.90	17,368.03	13,822.53
(c) Other current liabilities	4,742.95	3,631.53	5,082.97	4,586.03
(d) Short -term provisions	576.03	2,605.27	576.03	2,605.27
	25,072.48	20,499.70	24,319.53	21,176.40
TOTAL EQUITY AND LIABILITIES	134,157.01	122,167.99	128,426.62	116,867.68
II. ASSETS				
(1) Non-current assets				
(a) Fixed assets				
(i) Tangible assets	38,119.98	39,586.60	40,074.76	41,294.46
(ii) Intangible assets	-	-	237.88	304.54
(iii) Capital work-in-progress	23,265.12	11,866.07	23,713.47	12,264.29
	61,385.10	51,452.67	64,026.11	53,863.29
(b) Non-current Investment	10,243.10	11,760.90	545.26	583.21
(c) Deferred Tax Assets	-	-	1,015.94	1,518.23
(d) Long term loans and advances	3,041.85	4,459.17	3,045.72	4,460.94
(2) Current assets				
(a) Current Investments	800.00	3,503.92	800.00	3,503.92
(b) Inventories	20,065.54	18,548.31	23,057.06	20,767.97
(c) Trade receivables	26,538.73	20,619.35	22,074.71	19,157.72
(d) Cash & Bank Balances	1,094.10	1,971.05	2,012.61	2,698.21
(e) Short term Loans and advances	9,720.68	8,604.46	10,581.30	9,168.03
(f) Other current assets	1,267.91	1,148.16	1,267.91	1,148.16
	59,486.96	54,495.25	59,793.59	56,442.01
TOTAL ASSETS	134,157.01	122,167.99	128,426.62	116,867.68

7 Previous period / year figures have been regrouped / reclassified wherever necessary.

By Order of the Board
For Unichem Laboratories Limited

Place: Mumbai
Date: 20 May, 2016

Dr. Prakash A. Mody
Chairman & Managing Director

UNICHEM-A TRUSTED NAME IN PHARMACEUTICALS



**UNICHEM
LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198

Tel. No. : 91 (22) 66888333

Website : <http://www.unichemlabs.com>

CIN : L99999MH1962PLC012451.


Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

Form A


Covering letter of the Standalone Annual Audit Report to be filed with the Stock Exchanges

Name of the Company	Unichem Laboratories Limited
Annual financial statements for the year ended 31.3.2016	March 31, 2016
Type of Audit observation	Emphasis of Matter in the Independent Auditor's Report on the Standalone Financial Statements. "We draw attention to Note 34 to the standalone financial statements relating to increase in the provision for diminution of long-term investments in Unichem Farmaceutica Do Brazil Ltda, from Rs. 434.5 lacs in the previous year to Rs. 2,277.63 lacs for the year under report, based on internal assessment and other factors more elaborately stated in the said Note. Our opinion is not modified in respect of this matter."
Frequency of observation	Appeared for the first time.

For Unichem Laboratories Limited



Dr. Prakash A. Mody
Chairman & Managing Director

B. D. Jokhakar & Co
Chartered accountants



Raman Jokhakar
Partner
Firm Registration No:104345W
Membership no: 103241

Date : May 20, 2016

For Unichem Laboratories Limited


Rakesh Parikh
Chief Finance and compliance officer

For Unichem Laboratories Limited


Prafull Anubhai
Chairman of Audit committee

UNICHEM-A TRUSTED NAME IN PHARMACEUTICALS



**UNICHEM
LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198

Tel. No. : 91 (22) 66888333

Website : <http://www.unichemlabs.com>

CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

Form A

Covering letter of the Consolidated Annual Audit Report to be filed with the Stock Exchanges

Name of the Company	Unichem Laboratories Limited
Annual financial statements for the year	March 31, 2016
Type of Audit observation	Emphasis of Matter in the Independent Auditor's Report on the Consolidated Financial Statements "We draw attention to Note 29 to the Consolidated Financial Statements related to the outcome of fine imposed by European Commission jointly and severally against the Holding Company with its subsidiary, amounting to Euro 13.97 Million. Our opinion is not modified in respect of this matter."
Frequency of observation	The same note appeared in the Limited Review Report on the Statement of Unaudited Financial Results for the Quarter ended June 30, 2014 and Independent Auditor's Report on the Audited Consolidated Financial Statements for the year ended March 31, 2015. It was reported in Form A in terms of the reporting requirements.

For Unichem Laboratories Limited

Dr. Prakash A. Mody
Chairman & Managing Director

B. D. Jokhakar & Co
Chartered accountants

Raman Jokhakar
Partner

Firm Registration No:104345W

Membership no: 103241

Date : May 20, 2016

For Unichem Laboratories Limited

Rakesh Parikh
Chief Finance and compliance officer

For Unichem Laboratories Limited

Prafull Anubhai
Chairman of Audit committee

UNICHEM-A TRUSTED NAME IN PHARMACEUTICALS